Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3525287 | 0.98 | EPHX2 (0.54) | EPHX2ALDH1A1L3MBTL1TDP1FAAH | |
| SCHEMBL27274906 | 0.98 | EPHX2 (0.54) | EPHX2ALDH1A1L3MBTL1TDP1FAAH | |
| SCHEMBL18641735 | 0.98 | EPHX2 (0.54) | EPHX2ALDH1A1L3MBTL1TDP1FAAH | |
| SCHEMBL543078 | 0.95 | ALDH1A1 (0.53) | EPHX2ALDH1A1L3MBTL1TDP1TSHR | |
| SCHEMBL8824059 | 0.91 | NAAA (0.50) | EPHX2L3MBTL1TDP1FAAHNAAA | |
| SCHEMBL711863 | 0.87 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1TDP1TSHRHTT | |
| SCHEMBL9150244 | 0.87 | EPHX2 (0.51) | EPHX2ALDH1A1L3MBTL1TDP1FAAH | |
| SCHEMBL712393 | 0.86 | MAPT (0.56) | EPHX2L3MBTL1TDP1FAAHTSHR | |
| SCHEMBL19255575 | 0.85 | ALDH1A1 (0.47) | EPHX2ALDH1A1L3MBTL1TDP1TSHR | |
| SCHEMBL9574169 | 0.85 | ALDH1A1 (0.59) | ALDH1A1TDP1FAAHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11534434-B2 | Xanomeline derivatives and methods for treating neurological disorders | Karuna Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11534434-B2 | Xanomeline derivatives and methods for treating neurological disorders | Karuna Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210145810-A1 | XANOMELINE DERIVATIVES AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Karuna Therapeutics, Inc. | 2021-05-20 | — | — | US | disclosed |
| WO-2021097427-A1 | XANOMELINE DERIVATIVES AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Karuna Therapeutics, Inc. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021097427-A1 | XANOMELINE DERIVATIVES AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Karuna Therapeutics, Inc. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210145810-A1 | XANOMELINE DERIVATIVES AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Karuna Therapeutics, Inc. | 2021-05-20 | — | — | US | disclosed |
| US-20180201592-A1 | 2-AMINO-1,3,4-THIADIAZINE AND 2-AMINO-1,3,4-OXADIAZINE BASED ANTIFUNGAL AGENTS | F2G LIMITED (GB) | 2018-07-19 | — | — | US | disclosed |
| EP-3322705-A1 | 2-AMINO-1,3,4-THIADIAZINE AND 2-AMINO-1,3,4-OXADIAZINE BASED ANTIFUNGAL AGENTS | F2G Limited (GB) | 2018-05-23 | — | — | EP | disclosed |
| US-9809588-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170291895-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-10-12 | — | — | US | disclosed |
| WO-2017009651-A1 | 2-AMINO-1,3,4-THIADIAZINE AND 2-AMINO-1,3,4-OXADIAZINE BASED ANTIFUNGAL AGENTS | F2G LIMITED (GB) | 2017-01-19 | — | — | WO | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160002204-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11534434-B2 | Xanomeline derivatives and methods for treating neurological disorders | CHRM1, RXFP3, NPY5R | EPHX2 3601/4885ALDH1A1 3587/4885L3MBTL1 1116/4885 |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | EPHX2 3658/4885ALDH1A1 882/4885L3MBTL1 1762/4885 |
| US-20160002204-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | EPHX2 3658/4885ALDH1A1 882/4885L3MBTL1 1762/4885 |
| US-20180201592-A1 | 2-AMINO-1,3,4-THIADIAZINE AND 2-AMINO-1,3,4-OXADIAZINE BASED ANTIFUNGAL AGENTS | NAT1, DPM1, IL4I1 | EPHX2 3359/4885ALDH1A1 492/4885L3MBTL1 4519/4885 |
| US-20170291895-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | EPHX2 3658/4885ALDH1A1 882/4885L3MBTL1 1762/4885 |
| US-20210145810-A1 | XANOMELINE DERIVATIVES AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | CHRM1, RXFP3, NPY5R | EPHX2 3601/4885ALDH1A1 3587/4885L3MBTL1 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.